1-14 of 14
Dan Lu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

John Goulding, Mark Jelcic, Daniel Morales-Mantilla, John Reiser, Alison O'Connor, Rina Mbofung, Alan Williams, Dan Lu, Bi-Huei Yang, Alma Gutierrez, Miguel Meza, Yijia Pan, Jonatan Tuncel, Bryan Hancock, Sean Sherman, Alec Witty, Eigen Peralta, Martin Hosking, Lilly Wong, Tom Lee, Jode Goodridge, Bahram Valamehr
Journal: Blood
Blood (2024) 144 (Supplement 1): 4801.
https://doi.org/10.1182/blood-2024-209465
Published: 2024
Journal Articles

A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK Cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape

Eigen Peralta, Dan Lu, Mark Landon, Hui-yi Chu, Soo Park, Masanao Tsuda, Trevor Zarecki, Elena Demeester, Matthew Denholtz, Amit Mehta, Earl Avramis, Philip Chu, Jeffrey Chen, Eric Sung, Alec Witty, Tom Lee, Bahram Valamehr
Journal: Blood
Blood (2022) 140 (Supplement 1): 7429–7430.
https://doi.org/10.1182/blood-2022-169887
Published: 2022
Journal Articles

SUZ12 Participates in PNH Cloning Proliferation By Regulating Histone H3K27me3 Methylation Level

Rong Fu, Yingying Chen, Zonghong Shao, Hui Liu, Lijie Zeng, Liyan Li, Dan Lu, Zhaoyun Liu
Journal: Blood
Blood (2021) 138 (Supplement 1): 1106.
https://doi.org/10.1182/blood-2021-148546
Published: 2021
Journal Articles

Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment

Eigen Peralta, PhD, David Robbins, BS, Emily Carron, PhD, Matthew Denholtz, PhD, Natalie Navarrete, BS, Dan Lu, PhD, Joyee Yao, Sandeep Kothapally Hanok, Yinghui Sui, PhD, Angela Gentile, Eric Sung, Jason ORourke, PhD, Tom Lee, PhD, Daniel Shoemaker, PhD, Cokey Nguyen, PhD, Bahram Valamehr, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12.
https://doi.org/10.1182/blood-2020-141506
Published: 2020
Journal Articles

Multiplexed Engineered, Off-the-Shelf T Cells Carrying Three Tumor-Associated Antigen-Targeting Modalities: CAR + Pan-Tumor Targeting TCR + CD16 Fc Receptor

Cokey Nguyen, PhD, Eigen Peralta, PhD, Chia-Wei Chang, Wen-I Yeh, PhD, Yijia Pan, PhD, Dan Lu, PhD, May Sumi, Mochtar Pribadi, PhD, Bi-Huei Yang, PhD, Eric Sung, Alec Witty, PhD, Tom Lee, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32.
https://doi.org/10.1182/blood-2020-141507
Published: 2020
Journal Articles

PTENα promotes neutrophil chemotaxis through regulation of cell deformability

Yunqiao Li, Yuan Jin, Bowen Liu, Dan Lu, Minglu Zhu, Yan Jin, Michael A. McNutt, Yuxin Yin
Journal: Blood
Blood (2019) 133 (19): 2079–2089.
https://doi.org/10.1182/blood-2019-01-899864
Published: 2019
Includes: Multimedia, Supplemental data
Journal Articles

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Dan Lu, Jin Yan Jin, Leonid Gibiansky, William R. Gillespie, Priya Agarwal, Cheryl Jones, Yu-Waye Chu, Michael K. Wenger, Jamie Hirata, Chunze Li, Sandhya Girish
Journal: Blood
Blood (2015) 126 (23): 1525.
https://doi.org/10.1182/blood.V126.23.1525.1525
Published: 2015
Journal Articles

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Franck Morschhauser, MD PhD, Ian Flinn, Ranjana H Advani, MD, Catherine S. Diefenbach, MD, Kathryn Kolibaba, MD, Oliver W. Press, MD PhD, Laurie H Sehn, MD MPH, Andy I Chen, MDPhD, Gilles Salles, MD PhD, Herve Tilly, MD, Bruce D. Cheson, MD, Sarit Assouline, MD MSc, Martin Dreyling, Anton Hagenbeek, MD PhD, Pier Luigi Zinzani, MD, Sreeni Yalamanchili, BSPharm, Dan Lu, PhD, Cheryl Jones, PhD, Surai Jones, PhD, Yu-Waye Chu, Jeff P. Sharman, MD
Journal: Blood
Blood (2014) 124 (21): 4457.
https://doi.org/10.1182/blood.V124.21.4457.4457
Published: 2014
Journal Articles

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Ranjana Advani, MD, Andy I. Chen, MD, PhD, Daniel Lebovic, MD, Mark W. Brunvand, MD, Andre Goy, MD, Julie E. Chang, MD, Ephraim Hochberg, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Bruce D. Cheson, M.D.
Journal: Blood
Blood (2013) 122 (21): 4399.
https://doi.org/10.1182/blood.V122.21.4399.4399
Published: 2013
Journal Articles

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Gilles Andre Salles, MD, PhD, Myron S. Czuczman, MD, Sarit E. Assouline, MD, Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, Manish Patel, MD, Randeep Sangha, Herve Tilly, MD, Ranjana Advani, MD, Olivier Casasnovas, MD, Oliver W. Press, MD, PhD, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Franck Morschhauser
Journal: Blood
Blood (2013) 122 (21): 4400.
https://doi.org/10.1182/blood.V122.21.4400.4400
Published: 2013
Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Suzanne Trudel, MD, P. Leif Bergsagel, MD, Seema Singhal, M.D., Ruben Niesvizky, MD, Raymond L. Comenzo, MD, William I. Bensinger, MD, Daniel Lebovic, MD, YounJeong Choi, Dan Lu, Dorothy French, Elicia Penuel, William Ho, MD, PhD, Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2012) 120 (21): 4029.
https://doi.org/10.1182/blood.V120.21.4029.4029
Published: 2012
Journal Articles

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ranjana Advani, MD, Daniel Lebovic, MD, Mark Brunvand, MD, Andy I. Chen, MD, PhD, Andre Goy, MD, Julie E. Chang, MD, Lauren S Maeda, MD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Bruce D. Cheson, MD
Journal: Blood
Blood (2012) 120 (21): 59.
https://doi.org/10.1182/blood.V120.21.59.59
Published: 2012
Journal Articles

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, MPH, Manish Patel, MD, Randeep Sangha, MD, Myron S. Czuczman, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, Ranjana Advani, MD, Oliver W. Press, MD, PhD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline, MD
Journal: Blood
Blood (2012) 120 (21): 56.
https://doi.org/10.1182/blood.V120.21.56.56
Published: 2012
Journal Articles

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody

Yiwen Li, Hongli Li, Mei-Nai Wang, Dan Lu, Rajiv Bassi, Yan Wu, Haifan Zhang, Paul Balderes, Dale L. Ludwig, Bronislaw Pytowski, Paul Kussie, Obdulio Piloto, Donald Small, Peter Bohlen, Larry Witte, Zhenping Zhu, Daniel J. Hicklin
Journal: Blood
Blood (2004) 104 (4): 1137–1144.
https://doi.org/10.1182/blood-2003-07-2585
Published: 2004
Includes: Supplemental data